# Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

> **NCT04203160** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 75 (actual)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** CPI 613
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04203160
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-23
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-04-29
- **Target enrollment:** 75 (ACTUAL)
- **Why stopped:** Loss of funding
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04203160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04203160, "Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04203160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*